Assessing the safety and tolerability of a single IV dose of AZD9742 in healthy elderly male and female subjects
Study identifier:D2690C00007
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
A Phase I, Double-blind, Randomized, Placebo-Controlled Study to Assess the Safety and Tolerability, and Pharmacokinetics of a Single Dose of AZD9742 in Healthy Elderly Male and Female Volunteers
Medical condition
Tolerability, Healthy, elderly
Phase
Phase 1
Healthy volunteers
Yes
Study drug
AZD9742, Placebo
Sex
All
Actual Enrollment
12
Study type
Interventional
Age
65 Years +
Date
Study Start Date: 01 Jun 2010
Primary Completion Date: 01 Jul 2010
Study Completion Date: 01 Jul 2010
Study design
Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Double Blind
Primary Purpose: Treatment
Verification:
Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|---|
| Experimental: 1 Single dose of 750mg of intravenous AZD9742 in healthy elderly volunteers | Drug: AZD9742 Sterile solution, 620 mg (20 mg/mL) in 50 mL vial with a fill volume of 31 mL |
| Placebo Comparator: 2 Sterile 5% dextrose solution | Drug: Placebo Sterile 5% dextrose solution |
Contacts
Investigators
Principal Investigator
Billings W Billings
Bio-Kinetic 1816 W. Mt Vernon, Springfield, MO 65802
